Bevacizumab in the therapy for refractory metastatic colorectal cancer

Biologics: Targets and Therapy

Volumn 2, Issue 1, 2008, Pages 53-60

  Mulcahy, Mary F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Refractory

Indexed keywords

EID: 80052039598     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s1519     Document Type: Review

References (37)

1. Cassidy JCS, Diaz-Rubio E, Scheithauer W, et al. 2007. XELOX vs. FOLFOX4: Effi cacy results from XELOX-1/NO16966, a randomized phase III trial in fi rst-line metastatic colorectal cancer (MCRC). In Grunberg SM. (Ed.) 2007, Gastrointestinal Cancers Symposium, Orlando Florida, American Society of Clinical Oncology.
2. kChen HX, Mooney M, Boron M, et al. 2006. Phase II multicenter trial of bevacizumab plus fl uorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol, 24:3354-60.
3. Colucci G, Gebbia V, Paoletti G, et al. 2005. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol, 23:4866-75.
4. Cunningham D, Humblet Y, Siena S, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351, 337-45.
5. Cunningham D, Pyrhonen S, James RD, et al. 1998. Randomised trial of irinotecan plus supportive care versus supportive care alone after fl uorouracil failure for patients with metastatic colorectal cancer. Lancet, 352:1413-8.
6. De Gramont A, Figer A, Seymour M, et al. 2000. Leucovorin and fl uorouracil with or without oxaliplatin as fi rst-line treatment in advanced colorectal cancer. J Clin Oncol, 18:2938-47.
7. Douillard JY, Cunningham D, Roth AD, et al. 2000. Irinotecan combined with fl uorouracil compared with fl uorouracil alone as fi rst-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355:1041-7.
8. Ellis LM, Takahashi Y, Liu W, et al. 2000. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist, 5(Suppl 1):11-5.
9. Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr Rev, 18:4-25.
10. Giantonio BJ, Catalano PJ, Meropol NJ, et al. 2007. Bevacizumab in combination with oxaliplatin, fl uorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25. 1539-44.
11. Goldberg RM, Sargent DJ, Morton RF, et al. 2004. A randomized controlled trial of fl uorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 22:23-30.
12. Grothey A, Sargent D, Goldberg RM, et al. 2004. Survival of patients with advanced colorectal cancer improves with the availability of fl uorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 22:1209-14.
13. Grothey A, Sugrue M, Hedrick E, et al. And The Brite Study Investigators. 2007. Association between exposure to bevacizumab (BV. beyond fi rst progression (BBP. and overall survival (OS. in patients (pts. with metastatic colorectal cancer (mCRC.: Results from a large observational study (BRiTE. J Clin Oncol 2007 ASCO Annual Meeting Proceedings, 25.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. 2004. Bevacizumab plus irinotecan, fl uorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350:2335-42.
15. Hurwitz HI, Honeycutt W, Haley S, et al. 2006. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. Clin Colorectal Cancer, 6:66-9.
16. Ince WL, Jubb AM, Holden SN, et al. 2005. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst, 97:981-9.
17. Jain RK. 1994. Barriers to drug delivery in solid tumors. Sci Am, 271:58-65.
18. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307:58-62.
19. Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA Cancer J Clin, 57:43-66.
20. Jubb AM, Hurwitz HI, Bai W, et al. 2006. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol, 24:217-27.
21. Jubb AM, Pham TQ, Hanby AM, et al. 2004. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol, 57:504-12.
22. Kabbinavar FF, Hambleton J, Mass RD, et al. 2005a. Combined analysis of effi cacy: the addition of bevacizumab to fl uorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol, 23:3706-12.
23. Kabbinavar FF, Schulz J, McCleod M, et al. 2005b. Addition of bevacizumab to bolus fl uorouracil and leucovorin in fi rst-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 23:3697-705.
24. Kim KJ, Li B, Winer J, et al. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362:841-4.
25. Maindrault-Goebel F, De Gramont A, Louvet C, et al. 2000. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fl uorouracil continuous infusion regimens (FOLFOX. in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol, 11:1477-83.
26. Maindrault-Goebel F, De Gramont A, Louvet C, et al. 2001. High-dose intensity oxaliplatin added to the simplifi ed bimonthly leucovorin and 5-fl uorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer, 37:1000-5.
27. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. GERCOR. 2007. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings, 25.
28. Manley PW, Martiny-Baron G, Schlaeppi JM, et al. 2002. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs, 11:1715-36.
29. Rothenberg ML, Oza AM, Bigelow RH, et al. 2003. Superiority of oxaliplatin and fl uorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fl uorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol, 21:2059-69.
30. Rougier P, Van Cutsem E, Bajetta E, et al. 1998. Randomised trial of irinotecan versus fl uorouracil by continuous infusion after fl uorouracil failure in patients with metastatic colorectal cancer. Lancet, 352:1407-12.
31. Saltz LB, Cox JV, Blanke C, et al. 2000. Irinotecan plus fl uorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 343:905-14.
32. Saltz LB, Diaz-Rubio E, Scheithauer W, et al. 2007. Bevacizumab (Bev. in combination with XELOX or FOLFOX4: Effi cacy results from XELOX-1/NO16966, a randomized phase III trial in the fi rst-line treatment of metastatic colorectal cancer (MCRC). In Grunberg SM. (Ed). 2007 Gastrointestinal Cancers Symposium, Orlando Florida, American Society of Clinical Oncology.
33. Saltz LB, Hochster H, Wadler S, et al. 2005. Randomized phase II Trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 23.
34. Tournigand C, Andre T, Achille E, et al. 2004. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22:229-37.
35. Tournigand C, Cervantes A, Figer A, et al. 2006. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer -a GERCOR study. J Clin Oncol, 24:394-400.
36. Willett CG, Boucher Y, Di Tomaso E, et al. 2004. Direct evidence that the VEGF-specifi c antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10:145-7.
37. Yang JC, Haworth L, Sherry RM, et al. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349:427-34